On February 17, 2020 BiomX, a microbiome company developing both natural and engineered phage therapies, reported that the company will present pre-clinical data from its colorectal cancer program at the plenary session of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Microbiome, Viruses, and Cancer Conference taking place from February 21-24, 2020, in Orlando, Florida (Press release, BiomX, FEB 17, 2020, View Source [SID1234554398]). BiomX’s colorectal cancer program utilizes phage to target bacteria that are naturally present within tumors, with the aim of converting ‘cold’ tumors to ‘hot’ by delivering a payload (i.e. an immunostimulatory payload) to the tumor and eradicating tumor-protective bacteria.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation are as follows:
Abstract Title: "Novel Phages Targeting The Intratumor Associated Bacteria Fusobacterium Nucleatum"
Date: Sunday, February 23, 2020
Time: 10:15 a.m. – 12:15 p.m. ET
Plenary Session 5: Oncogenic Viruses, Part 2
Poster Number: B20
About Phage Therapy
Bacteriophage, or phage, are viruses that target bacteria and are considered inert to mammalian cells. Phage are designed to target and kill specific bacterial species or strains without disrupting other bacteria or the healthy microbiota. All of BiomX’s phage-based product candidates derive from its proprietary platform, which is first used to discover and validate the association of specific bacterial strains with human diseases or conditions, and is then used to develop rationally-designed phage combinations ("cocktails") of naturally occurring or synthetic phage to target pathogenic bacteria. The phage cocktails contain multiple phage with complementary functions optimized through in vitro and in vivo testing.